Posted by kinasepro on November 4, 2006
Hi TargeGen, I see you’ve got another handful of compounds in another SRC inhibitor application. I guess selectivity has never been a real big thing down there in San Diego. These look suspiciously like dasatinib and are just the ‘reverse-amides’ from an earlier TG series (WO2006101977). I wonder what the ABL inhibition looks like for these…
Nice work finding a niche that doesn’t seem to have been covered anyhow.